The Cancer Committee of FirstHealth Moore Regional Hospital, chaired by Dr. Ellen Willard, is pleased to present this statistical overview of the MRH Cancer Program in 2010 and a major site report on breast cancer. The MRH Cancer Program is accredited with commendation by the American College of Surgeons Commission on Cancer (ACoS CoC) as a Community Hospital Comprehensive Cancer Program. This voluntary accreditation program encourages facilities to demonstrate availability of all major modalities of cancer treatment and meet rigorous requirements for multidisciplinary medical and hospital staff interaction, patient support services, community outreach activities, quality improvement and outcomes analyses.

Each cancer program must undergo a rigorous evaluation and review of its performance and compliance with the CoC standards. To maintain accreditation, facilities with accredited cancer programs must undergo an on-site review every three years.

The most recent on-site review of the MRH cancer program occurred in May 2011. We are pleased to report that the program received a full accreditation with Commendation. As a result of the 2008 survey, the MRH cancer program was awarded the Outstanding Achievement Award. Only 95 programs in the United States received the OAA as a result of surveys performed in 2008. This number represents approximately 19 percent of the 478 programs surveyed during this period. The recipients of the 2011 OAA will be announced in 2012.

Our accreditation ensures that each individual with cancer being treated at MRH will receive quality care close to home, including:
- Comprehensive care offering a range of state-of-the-art services and equipment
- A multidisciplinary team approach to coordinate the best cancer treatment options available
- Access to cancer-related information, education and support
- Ongoing monitoring and improvement of care
- Information about clinical trials and new treatment options

Thank you for taking the time to review this report. If you would like additional information about FirstHealth of the Carolinas, or any of the information presented in this overview, please feel free to contact us by calling (800) 213-3284.

State and National Comparisons
2010 Most Prevalent Cancer Cases by Number of Cases and Percentage

<table>
<thead>
<tr>
<th></th>
<th>MRH</th>
<th>NC*</th>
<th>US**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast</td>
<td>188</td>
<td>16.4</td>
<td>6,500</td>
</tr>
<tr>
<td>Lung</td>
<td>262</td>
<td>22.9</td>
<td>7,520</td>
</tr>
<tr>
<td>Prostate</td>
<td>172</td>
<td>15</td>
<td>6,910</td>
</tr>
<tr>
<td>Colorectal</td>
<td>91</td>
<td>8</td>
<td>4,220</td>
</tr>
<tr>
<td>Bladder</td>
<td>48</td>
<td>4.2</td>
<td>1,890</td>
</tr>
<tr>
<td>NHLymphoma</td>
<td>40</td>
<td>3.5</td>
<td>1,800</td>
</tr>
<tr>
<td>Corpus Uteri</td>
<td>16</td>
<td>1.4</td>
<td>1,190</td>
</tr>
<tr>
<td>Melanoma</td>
<td>15</td>
<td>1.3</td>
<td>2,130</td>
</tr>
<tr>
<td>Leukemia</td>
<td>6</td>
<td>.5</td>
<td>1,150</td>
</tr>
<tr>
<td>Cervix</td>
<td>1</td>
<td>.1</td>
<td>360</td>
</tr>
<tr>
<td>All Others</td>
<td>304</td>
<td>26.6</td>
<td>11,450</td>
</tr>
<tr>
<td>Total Cases</td>
<td>1,143</td>
<td>100</td>
<td>45,120</td>
</tr>
</tbody>
</table>

Throughout this report, percentages may not always total 100% due to rounding. This report excludes basal and squamous cell skin cancers and in situ lesions of all sites except bladder. State and national numbers are estimates of cancer incidence in the entire state and nation, regardless of where the patient is treated. The FHMRH numbers, however, are actual cases that were diagnosed and treated at MRH, regardless of where the patient lives. This, along with the age of the local population, may explain deviations from the state and national averages.

*American Cancer Society, 2010 Cancer Statistics, Estimated new cases.

County of Residence at Time of Treatment
2010 New and Recurrent Cancer Cases

<table>
<thead>
<tr>
<th>Current County</th>
<th>Cases</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moore</td>
<td>647</td>
<td>47.40</td>
</tr>
<tr>
<td>Richmond</td>
<td>193</td>
<td>14.10</td>
</tr>
<tr>
<td>Lee</td>
<td>96</td>
<td>7.00</td>
</tr>
<tr>
<td>Robeson</td>
<td>88</td>
<td>6.50</td>
</tr>
<tr>
<td>Hoke</td>
<td>81</td>
<td>6.00</td>
</tr>
<tr>
<td>Montgomery</td>
<td>75</td>
<td>5.50</td>
</tr>
<tr>
<td>Scotland</td>
<td>68</td>
<td>5.00</td>
</tr>
<tr>
<td>Cumberland</td>
<td>39</td>
<td>3.00</td>
</tr>
<tr>
<td>Chatham</td>
<td>16</td>
<td>1.00</td>
</tr>
<tr>
<td>Harnett</td>
<td>12</td>
<td>.88</td>
</tr>
<tr>
<td>Anson</td>
<td>10</td>
<td>.73</td>
</tr>
<tr>
<td>Marlboro (SC)</td>
<td>9</td>
<td>.68</td>
</tr>
<tr>
<td>Randolph</td>
<td>8</td>
<td>.59</td>
</tr>
<tr>
<td>Chesterfield (SC)</td>
<td>6</td>
<td>.45</td>
</tr>
<tr>
<td>Other NC</td>
<td>6</td>
<td>.45</td>
</tr>
<tr>
<td>Out of State</td>
<td>5</td>
<td>.37</td>
</tr>
<tr>
<td>Stanly</td>
<td>3</td>
<td>.22</td>
</tr>
<tr>
<td>Alamance</td>
<td>2</td>
<td>.15</td>
</tr>
<tr>
<td>Total Cases</td>
<td>1,364</td>
<td>100.00</td>
</tr>
</tbody>
</table>

Most Frequently Diagnosed/Treated Cancers at Moore Regional Hospital

<table>
<thead>
<tr>
<th>Year</th>
<th>Breast</th>
<th>Lung</th>
<th>Prostate</th>
<th>Colon/Rectum</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>195</td>
<td>217</td>
<td>149</td>
<td>132</td>
</tr>
<tr>
<td>2006</td>
<td>197</td>
<td>248</td>
<td>160</td>
<td>111</td>
</tr>
<tr>
<td>2007</td>
<td>213</td>
<td>229</td>
<td>171</td>
<td>99</td>
</tr>
<tr>
<td>2008</td>
<td>201</td>
<td>206</td>
<td>168</td>
<td>85</td>
</tr>
<tr>
<td>2009</td>
<td>210</td>
<td>228</td>
<td>164</td>
<td>114</td>
</tr>
<tr>
<td>2010</td>
<td>218</td>
<td>262</td>
<td>172</td>
<td>97</td>
</tr>
</tbody>
</table>

Age By Gender
All 2010 Cases

<table>
<thead>
<tr>
<th>Age</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>10-19</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>20-29</td>
<td>2</td>
<td>7</td>
</tr>
<tr>
<td>30-39</td>
<td>6</td>
<td>24</td>
</tr>
<tr>
<td>40-49</td>
<td>29</td>
<td>66</td>
</tr>
<tr>
<td>50-59</td>
<td>114</td>
<td>117</td>
</tr>
<tr>
<td>60-69</td>
<td>235</td>
<td>190</td>
</tr>
<tr>
<td>70-79</td>
<td>197</td>
<td>161</td>
</tr>
<tr>
<td>80-89</td>
<td>97</td>
<td>87</td>
</tr>
<tr>
<td>90-99</td>
<td>10</td>
<td>11</td>
</tr>
<tr>
<td>Total</td>
<td>693</td>
<td>663</td>
</tr>
</tbody>
</table>

Within the FHMRH Cancer Registry, this report excludes cancers diagnosed and treated elsewhere and treated at MRH for recurrence.
Cancer Registry Data Overview 2011

In 2010, the FirstHealth Moore Regional Hospital Cancer Registry recorded 1,364 cancer cases, representing a slight increase from the 1,328 cases documented in 2009. In order of incidence, lung, breast, prostate and colorectal cancer were the most commonly diagnosed. This is similar to state and national averages with the exception of lung cancer, which accounted for 22.9 percent of newly diagnosed cases at MRH, but only 16.7 percent in North Carolina and 14.5 percent nationally. This has been a consistent finding over the past decade and is likely due to a disproportionate volume of referrals to local sub-specialists for diagnosis and treatment of thoracic lesions.

A diagnosis of cancer was clearly related to age, with people aged 60 years and older accounting for 73 percent of cases. The racial distribution of the patient population is similar to that of the local area with approximately 73 percent of cases occurring among Caucasians, 22 percent among African-Americans and 5 percent among American Indians. Hispanic patients are included in the Caucasian category since this term is considered an ethnic rather than a racial designation.

Cancer Registries are required by state law to collect, manage and analyze data related to cancer diagnosis and treatment. Ninety-five percent of the cases were presented prospectively, indicating that multidisciplinary input could affect future treatment decisions. Three nationally certified cancer registrars perform these extensive procedures in addition to organizing and assisting with weekly cancer conferences. Thirty-five requests for specific analyses related to the MRH cancer program data were fulfilled. In 2010, 494 cases were presented for review at 98 multidisciplinary conferences for discussion by a group of physicians representing all specialties involved in the diagnosis and treatment of cancer. Ninety-five percent of the cases were presented prospectively, indicating that multidisciplinary input could affect future treatment decisions.

Early cancer detection can be attributed to patient education and awareness of warning signs, self-examinations and regular medical screening including physicals, mammograms, PSA testing, fecal occult blood testing, colonoscopies and gynecological exams/PAP smears. In keeping with the referral patterns of past years, 47 percent of the patients who were diagnosed and/or treated at Moore Regional’s Community Hospital Comprehensive Cancer Center were residents of Richmond County. An additional 14 percent of patients are residents of Moore County. Between 5 and 7 percent of patients travel to MRH from each of the following counties: Lee, Montgomery, Scotland, Robeson and Hoke. The remaining patients reside in more distant areas.

While 89 percent of patients were treated at MRH, 5 percent were diagnosed here but treated elsewhere. This figure reflects the philosophy that certain types of cancers require services and technologies available only at a university-based teaching hospital. Examples of these services and technologies are high-dose chemotherapy with bone marrow support and management of most pediatric cancer cases. The remaining 8 percent of reported cases were either pathology reports from outside offices or were diagnosed and treated in a staff physician’s office. Those patients did not enter MRH for diagnosis or treatment.

Collecting, managing and analyzing data related to cancer diagnosis and treatment is a vital part of the cancer program at MRH. The follow-up rate of 95 percent for treated patients far exceeds the American College of Surgeons (ACoS) program standard. Requested data is forwarded to both the N.C. Central Cancer Registry, as required by state law, and to the American College of Surgeons National Cancer Data Base, as required for an accredited Community Hospital Comprehensive Cancer Program. In accordance with HIPAA guidelines, strict patient confidentiality measures are followed.

Three nationally certified cancer registrars perform these extensive procedures in addition to organizing and assisting with weekly cancer conferences. Thirty-five requests for specific analyses related to the MRH cancer program data were fulfilled. In 2010, 494 cases were presented for review at 98 multidisciplinary conferences for discussion by a group of physicians representing all specialties involved in the diagnosis and treatment of cancer. Ninety-five percent of the cases were presented prospectively, indicating that multidisciplinary input could affect future treatment decisions.

Jeffrey C. Acker, M.D.
Medical Director
FHMRH Community Hospital Comprehensive Cancer Center

2011 Summary for Clinical Trials at Moore Regional Hospital

Clinical trials are research studies to find better ways to prevent or treat disease. Each study is carefully designed to answer specific scientific questions. These studies are the final stages of a long and careful cancer research process to determine the value of promising approaches to cancer prevention, diagnosis and treatment.

In the case of cancer, clinical trials often compare the most accepted cancer treatment (standard of care) with a new treatment that is hoped to be better based on laboratory and small-scale clinical research results. The studies help determine if new drugs, treatments, devices or approaches are safe and effective. Studies such as these are required for FDA approval of the drugs or treatments for future cancer patients. They are sponsored by the National Cancer Institute through its numerous research arms and the pharmaceutical industry.

FirstHealth Moore Regional Hospital has participated in clinical trials since 1997. As of the writing of this document, Moore Regional’s Clinical Trials office has 30 studies open for cancer patients. The studies were selected to offer patients additional treatment options with a focus on the cancer types most frequently seen at MRH. Patients in clinical studies must be referred by their physicians and are required to meet eligibility criteria to qualify for participation.
2011 Major Site Report: Breast Cancer

In 2011, an estimated 230,480 new cases of invasive breast cancer were diagnosed in women in the United States along with 37,650 new cases of noninvasive (in situ) breast cancer. About 2,140 new cases of invasive breast cancer were diagnosed in men in 2011. About one in eight women will develop invasive breast cancer over the course of their lifetime. A man’s lifetime risk is about one in 1,000. About 39,320 women in the United States died from breast cancer in 2011.

Besides skin cancer, breast cancer is the most commonly diagnosed cancer among American women, accounting for just under 30 percent of cancers in women. For women in the U.S., breast cancer trails only lung cancer for cancer-specific mortality.

Most breast cancers are diagnosed at an early stage. This is likely due to the accepted role of annual mammographic surveillance and tremendous self-awareness regarding the potential danger of a palpable breast mass. A total of 212 breast cancers were diagnosed within the FHMRH system in 2010. Fifty-four percent of those cases were diagnosed at an early stage (14 percent in situ, 40 percent stage 1). This is in keeping with the National Cancer Data Base (NCDB) figure of 58 percent. Stage of presentation of breast cancer diagnosis at FHMRH mirrors the NCDB across all stages (Table 1). Breast cancer incidence rates continue to demonstrate a downward trend. Female breast cancer incidence rates decreased by about 2 percent per year from 1999 to 2005. This trend was observed only in women aged 50 or older and was thought secondary to the decreased use of post-menopausal hormonal replacement therapy that occurred after the publication of the Women’s Health Initiative in 2002.

Although a significant number of breast cancers are hereditary in nature (due to an inherited mutation in BRCA1 and BRCA2 or other genes such as CHEK2, PTEN, ATM, or p53), most breast cancers are nonfamilial in nature. Other risk factors associated with an increased risk of breast cancer include dense breast tissue, aging, prior chest irradiation, diethylstilbestrol exposure, nulliparity, recent oral contraceptive use, hormonal replacement therapy, alcohol use and obesity.

Surgery remains the mainstay of treatment for breast cancer except in those patients who present with metastatic disease. However, the optimal therapy for the majority of breast cancer patients includes multiple modalities. Hormonal therapy, radiation therapy and chemotherapy play important roles in addition to surgery. A review of the FHMRH Cancer Registry data demonstrates that 84 percent of breast cancer patients received some sort of combination therapy (Table 2). This environment of cooperation across medical specialties is fostered at FHMRH through weekly tumor boards and clinical case conferences in which representatives of the departments of surgery, radiation oncology, medical oncology, pathology, diagnostic radiology, nursing, cancer registry and clinical trials all attend. Stage of disease, hormone receptor status and patient preference continue to be key drivers regarding the selection of appropriate treatment.

Significant trends noticed in the past four years since this institution’s last major site report on breast cancer include the following:
- An increased use of breast MRI imaging with the goal of detecting cancers at an earlier stage. This allows greater surgical options for a patient, hopefully improving the chance for long-term cure.
- Increased awareness and testing for the BRCA1 and 2 mutations. Armed with this information, patients may select an alternative surgical therapy and consider a prophylactic bilateral mastectomy and/or oophorectomy or opt for closer surveillance.
- Increased adoption of the Oncotype DX® diagnostic tool. This has contributed to the decreased use of adjuvant systemic therapy in the estrogen receptor-positive, lymph node-negative adjuvant breast cancer setting.

Use of these prognostic and predictive tools results in the avoidance of chemotherapy for women who are unlikely to benefit (and thus eliminate chemotherapy-associated toxicities), reserving chemotherapy for a more selective population of early-stage breast cancer that is likely to demonstrate some degree of benefit from the use of adjuvant chemotherapy. Other trends noticed since the last report include an increased utilization of the docetaxel/cyclophosphamide chemotherapy regimen and a decreased reliance on anthracycline-based therapies in the adjuvant setting.

Newly approved FDA agents such as ixabepilone, eribulin mesylate and lapatinib have all been successfully incorporated into the treatment plan for many of our metastatic breast cancer patients. There has not been significant uptake of the use of the FDA-approved preventive agent of tamoxifen or raloxifene within the FHMRH system.

Overall, significant progress has been made in the treatment of breast cancer, both nationally and at FHMRH. Death rates from breast cancer have been declining since 1990. Ninety percent of women diagnosed with invasive breast cancer will be alive five years after their diagnosis.

There are an estimated 2.63 million survivors of breast cancer within the United States as per the 2011 SEER database.

Some of these improvements are believed to be secondary to increased awareness, active screening programs, earlier stage of breast cancer diagnoses, the development of new breast cancer-specific therapies and the overall improvement of health care in general over the past number of years. Although tremendous strides have been made, much work lies ahead.

Charles S. Kuzma, M.D.
Medical Oncology/Hematology
PMC/FH Outpatient Cancer Center
Table 1
Stage at Diagnosis
2010 Breast Cancer

<table>
<thead>
<tr>
<th>Stage</th>
<th>NBR-Cases</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>29</td>
<td>13.68</td>
</tr>
<tr>
<td>I</td>
<td>85</td>
<td>40.09</td>
</tr>
<tr>
<td>II</td>
<td>60</td>
<td>28.30</td>
</tr>
<tr>
<td>III</td>
<td>30</td>
<td>14.15</td>
</tr>
<tr>
<td>IV</td>
<td>6</td>
<td>2.83</td>
</tr>
<tr>
<td>UNK</td>
<td>2</td>
<td>.94</td>
</tr>
<tr>
<td>Total Cases</td>
<td>212</td>
<td>100.00</td>
</tr>
</tbody>
</table>

Table 2
Treatment Combinations
2010 Breast Cancer

<table>
<thead>
<tr>
<th>Rx Type</th>
<th>NBR-Cases</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>SURG/RAD/HOR</td>
<td>53</td>
<td>25.00</td>
</tr>
<tr>
<td>SURG/HOR</td>
<td>36</td>
<td>16.98</td>
</tr>
<tr>
<td>SURG</td>
<td>33</td>
<td>15.57</td>
</tr>
<tr>
<td>SURG/CHEM/RAD/HOR</td>
<td>22</td>
<td>10.38</td>
</tr>
<tr>
<td>SURG/CHEM/RAD</td>
<td>20</td>
<td>9.43</td>
</tr>
<tr>
<td>SURG/RAD</td>
<td>19</td>
<td>8.96</td>
</tr>
<tr>
<td>SURG/CHEM</td>
<td>18</td>
<td>7.55</td>
</tr>
<tr>
<td>SURG/CHEM/HOR</td>
<td>6</td>
<td>2.83</td>
</tr>
<tr>
<td>OTHER COMBINATIONS</td>
<td>5</td>
<td>2.36</td>
</tr>
<tr>
<td>NONE</td>
<td>2</td>
<td>.94</td>
</tr>
<tr>
<td>Total Cases</td>
<td>212</td>
<td>100.00</td>
</tr>
</tbody>
</table>

Table 3
Observed Survival Analysis
2003-2005 Breast Cancer

<table>
<thead>
<tr>
<th>YEAR</th>
<th>Begin</th>
<th>MRH</th>
<th>North Carolina</th>
<th>Southern Division</th>
<th>All Programs</th>
</tr>
</thead>
<tbody>
<tr>
<td>YEAR 1</td>
<td>97.9</td>
<td>97.2</td>
<td>97.3</td>
<td>97.1</td>
<td></td>
</tr>
<tr>
<td>YEAR 2</td>
<td>95.6</td>
<td>93.9</td>
<td>93.9</td>
<td>93.9</td>
<td></td>
</tr>
<tr>
<td>YEAR 3</td>
<td>91.4</td>
<td>90.6</td>
<td>90.5</td>
<td>90.5</td>
<td></td>
</tr>
<tr>
<td>YEAR 4</td>
<td>88.2</td>
<td>87.7</td>
<td>87.4</td>
<td>87.4</td>
<td></td>
</tr>
<tr>
<td>YEAR 5</td>
<td>85.6</td>
<td>84.5</td>
<td>84.3</td>
<td>84.3</td>
<td></td>
</tr>
<tr>
<td>Total Cases</td>
<td>390</td>
<td>20539</td>
<td>130073</td>
<td>130711</td>
<td></td>
</tr>
</tbody>
</table>

American Cancer Society National Cancer Data Base
### Site and Stage Distribution

**Primary Site Tabulation for New 2010 Cases**

<table>
<thead>
<tr>
<th>Sites</th>
<th>Total</th>
<th>M</th>
<th>F</th>
<th>Stage 0</th>
<th>Stage I</th>
<th>Stage II</th>
<th>Stage III</th>
<th>Stage IV</th>
<th>Unknown</th>
<th>N/A</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALL SITES</td>
<td>1194</td>
<td>607</td>
<td>587</td>
<td>86</td>
<td>287</td>
<td>289</td>
<td>205</td>
<td>207</td>
<td>37</td>
<td>104</td>
</tr>
<tr>
<td>ORAL CAVITY</td>
<td>26</td>
<td>21</td>
<td>5</td>
<td>0</td>
<td>1</td>
<td>3</td>
<td>8</td>
<td>12</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>ESOPHAGUS</td>
<td>9</td>
<td>6</td>
<td>3</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>STOMACH</td>
<td>17</td>
<td>8</td>
<td>9</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>6</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>COLON</td>
<td>75</td>
<td>35</td>
<td>40</td>
<td>8</td>
<td>12</td>
<td>21</td>
<td>18</td>
<td>13</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>RECTUM</td>
<td>19</td>
<td>10</td>
<td>9</td>
<td>0</td>
<td>5</td>
<td>2</td>
<td>9</td>
<td>3</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>ANUS/ANAL CANAL</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>LIVER</td>
<td>9</td>
<td>6</td>
<td>3</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>3</td>
<td>4</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>PANCREAS</td>
<td>24</td>
<td>12</td>
<td>12</td>
<td>0</td>
<td>3</td>
<td>10</td>
<td>3</td>
<td>7</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>OTHER DIGESTIVE</td>
<td>21</td>
<td>9</td>
<td>12</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>9</td>
<td>1</td>
<td>6</td>
</tr>
<tr>
<td>NASAL/SINUS</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>LARYNX</td>
<td>17</td>
<td>14</td>
<td>3</td>
<td>1</td>
<td>3</td>
<td>5</td>
<td>4</td>
<td>4</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>LUNG/BRONCHUS</td>
<td>262</td>
<td>154</td>
<td>108</td>
<td>0</td>
<td>65</td>
<td>15</td>
<td>75</td>
<td>98</td>
<td>6</td>
<td>3</td>
</tr>
<tr>
<td>OTHER RESPIRATORY</td>
<td>4</td>
<td>3</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>LEUKEMIA</td>
<td>6</td>
<td>1</td>
<td>5</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>MULTIPLE MYELOMA</td>
<td>20</td>
<td>15</td>
<td>5</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>OTHER</td>
<td>5</td>
<td>3</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>CONNECT/SOFT TISSUE</td>
<td>6</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>MELANOMA</td>
<td>18</td>
<td>14</td>
<td>4</td>
<td>3</td>
<td>6</td>
<td>5</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>OTHER SKIN</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>BREAST</td>
<td>218</td>
<td>214</td>
<td>30</td>
<td>88</td>
<td>61</td>
<td>30</td>
<td>6</td>
<td>3</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>CERVIX UTERI</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>CORPUS UTERI</td>
<td>15</td>
<td>16</td>
<td>0</td>
<td>0</td>
<td>11</td>
<td>1</td>
<td>3</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>OVARY</td>
<td>12</td>
<td>12</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>4</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>VULVA</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PROSTATE</td>
<td>172</td>
<td>172</td>
<td>0</td>
<td>0</td>
<td>123</td>
<td>33</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>TESTIS</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>BLADDER</td>
<td>48</td>
<td>39</td>
<td>9</td>
<td>20</td>
<td>14</td>
<td>11</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>KIDNEY/Renal</td>
<td>37</td>
<td>20</td>
<td>17</td>
<td>0</td>
<td>22</td>
<td>1</td>
<td>4</td>
<td>6</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>OTHER URINARY SYSTEM</td>
<td>4</td>
<td>4</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>BRAIN (BENIGN)</td>
<td>6</td>
<td>5</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>BRAIN (MALIGNANT)</td>
<td>14</td>
<td>7</td>
<td>7</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>14</td>
</tr>
<tr>
<td>OTHER CNS</td>
<td>17</td>
<td>5</td>
<td>12</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>17</td>
</tr>
<tr>
<td>THYROID</td>
<td>40</td>
<td>39</td>
<td>1</td>
<td>31</td>
<td>0</td>
<td>29</td>
<td>3</td>
<td>7</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>OTHER ENDOCRINE</td>
<td>6</td>
<td>2</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>Hodgkin's Disease</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Non-Hodgkin's</td>
<td>40</td>
<td>15</td>
<td>25</td>
<td>0</td>
<td>12</td>
<td>9</td>
<td>3</td>
<td>15</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Unknown PRIMARY</td>
<td>11</td>
<td>4</td>
<td>7</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>11</td>
</tr>
<tr>
<td>OTHER/ILL-DEFINED</td>
<td>3</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>3</td>
</tr>
</tbody>
</table>

FHMRH CANCER REGISTRY
In today’s complex economy, not-for-profit health care organizations such as FirstHealth face an increasing challenge to provide high-quality care to patients in the most cost-effective manner. The future of reimbursement through insurance and governmental programs for these vital health services is uncertain, and while Americans are blessed with a multitude of health care options, these choices often come at an unexpected price.

The Cancer CARE Fund benefits patients in the primary FirstHealth service area of Moore, Montgomery, Richmond and Hoke counties, providing for such needs as transportation, medications, prostheses, wigs and other patients needs that arise during the course of treatment.

Thank you to the following individuals and organizations who generously supported the Cancer CARE Fund during Fiscal Year 2010-11 (October 1, 2010, to September 30, 2011). Our communities have consistently demonstrated their resolve to provide the financial support necessary to ensure the delivery of superior health care. In fact, one of the abiding strengths of our health system is its long-standing and successful partnership with the communities it serves.
Moore Regional Hospital Foundation – Cancer CARE Fund Benefactors (continued)

Dr. and Mrs. Joseph G. Gibbons
Mr. and Mrs. Thomas P. Giebner
Ms. Debbie L. Gilbert
Mr. and Mrs. Jeffrey R. Gilbert
Mr. and Mrs. James D. Gillis, Ill
Ms. Ellen Gleason
Mr. Chad Golden
Mrs. Margarett A. Goodfellow
Mrs. Connie G. Goodrum
Ms. Shannon E. Goodrum
Dr. and Mrs. Ted A. Graham
Mr. and Mrs. Jonathan M. Gribben
Mr. Michael Gringeri
Mr. and Mrs. Francis J. Guerra
Ms. Jennifer J. Guirvare
Mr. and Mrs. Oscar G. Gulley, IV
Mr. and Mrs. Damon Gulnac
Mr. and Mrs. Timothy S. Gulovich
Mr. and Mrs. Thomas G. Harley
Mr. and Mrs. Alfred M. Gustafson
Ms. Elizabeth K. Haddock
Mr. and Mrs. H. Wayne Haddock
Mr. Walter Halt
Mr. and Mrs. James R. Hall
Ms. Jane M. Hall
Mr. and Mrs. Jerry Hall
Mr. and Mrs. Doug Hamer
Dr. and Mrs. James M. Hamilton
Mr. Bobby Hancock
Mr. Kim Hand
Mr. and Mrs. C. Michael Haney
Mr. and Mrs. Thomas A. Haney
Ms. Kristie Hanshew
Ms. Joyce L. Hardtner
Mr. Douglas R. Hardisty
Mr. and Mrs. Brent G. Hargan
Mr. and Mrs. David L. Harper
Mr. Michael A. Harrell and Dr. Sharon N. Harrell
Mr. and Mrs. Joseph L. Harrington
Ms. Janet F. Harris
Mr. and Mrs. Joshua T. Harris
Ms. Connie P. Harrison
Ms. Melanie M. Harrison
Ms. Elizabeth W. Haskell
Mr. and Mrs. Jack Hatcher, Jr.
Mr. and Mrs. Donald E. Hauck
Mr. and Mrs. Ralph E. Hawes
Mr. Robert A. Hebert
Mr. and Mrs. Brian E. Heckle
Mr. Laurence F. Heiden
Mr. and Mrs. John Heimrich
Mr. and Mrs. David A. Hendrix
Mr. and Mrs. Floyd L. Hemdon
Mr. and Mrs. Peter G. Hessler
Mr. and Mrs. Roger V. Hicks
Mr. and Mrs. Jason Hilyard
Mr. and Mrs. David C. Hobson
Mr. Doug Hodson and Mrs. Laurie Hansch
Mr. and Mrs. John A. Hoffmann
Holden Thomasson & Longfellow, CPAs
Dr. and Mrs. Matthew Brady Holler
Ms. Denise Holliday
Dr. and Mrs. Scott A. Holliday
Ms. Marquita Holmes
Mr. and Mrs. David Holroyd
Mr. David Hope
Mr. and Mrs. William J. Horn
Ms. Patricia A. Hoskins
Mr. Mike Hove and Ms. Ashley Willis
Mr. and Mrs. Timothy H. Howie
Chaplain Pamela J. Hudson
Ms. Terri L. Hudson
Mr. and Mrs. Randall Hughes
Dr. Terry J. Hulihan and Dr. Shannon Allison
Ms. Cassina A. Hunt
Mr. and Mrs. Chris T. Hunt
Ms. Jessica L. Hyatt
Ms. Gail A. Hyde
Hyman & Johnson Construction, LLP
Mr. and Mrs. Patrick B. Inge
Mr. and Mrs. Adam Ingram
Mr. and Mrs. Ian Inquimby
The Insurance Center/The MGN Company
Ms. Cornelia Jackson
Mr. and Mrs. John J. Jackson
Mr. and Mrs. Herbert M. Jacobs
Mr. and Mrs. Nicholas C. James
Dr. Bruce P. Jaufmann and Dr. Carol M. Wadon
Mr. and Mrs. Jimmy Jenkins
Mr. and Mrs. Edwin F. Jennings
Mr. and Mrs. Mark W. Jessop
Mr. and Mrs. Albert F. Johnson
Ms. Becky Johnson
Mr. and Mrs. Reginald H. Jones
Ms. Cyndi A. Johnson
Ms. Dee Johnson
Mr. Eric B. Johnson
Mr. Rick Johnson and Mrs. Beverly Leblanc
Mr. and Mrs. Toby Johnson
Mr. and Mrs. William C. Johnston
Ms. Jaclyn A. Jones
Mr. and Mrs. Jason Jones
Mr. and Mrs. Jimmy M. Jones
Ms. Kimberly D. Jones
Mr. and Mrs. Reginald H. Jones
Mr. and Mrs. Russell L. Jones
Mr. and Mrs. Ben E. Jordan, Jr.
Ms. Janet Jordan
Mr. and Mrs. Randy K. Jordan Joseph’s Gallery
Mr. and Mrs. Marshall G. Joyner
Mr. and Mrs. Yasud Kamibayashi
Ms. Veronica Karaman
Peter R. & Cynthia K. Kellogg Foundation
Mr. and Mrs. Carl Kelly
Mr. Daniel W. Kelly
Ms. Emily B. Kent
Mr. and Mrs. G. S. Key
Mr. and Mrs. Christopher M. Kibler
Mr. Joshua Kilgore
Mr. and Mrs. Jeff Kinney
Ms. Katie J. Kinney
Dr. and Mrs. Stephen C. King
Mr. and Mrs. Donald L. Kingston, Jr.
Mr. and Mrs. Steven R. Kline
Ms. Jillian M. Klug
Mr. Jeremy Knabenhue
Ms. Melissa Knotoff
Mr. Timbo J. Kochy
Mr. Luke E. Koenssner
Mr. and Mrs. Don Koeze
Dr. and Mrs. Boltran W. Kopycz
Mr. and Mrs. Martin Korte
Dr. and Mrs. John F. Krahmert, Jr.
Ms. Thesene A. Kreutzberg
Ms. Chris A. Kubiak
Dr. and Mrs. Charles S. Kuzma
Dr. and Mrs. Paul J. Kuzma
Mr. and Mrs. Michael V. Lawless
Mr. David Lawrence
Mr. and Mrs. Anthony T. Lawes
Mr. and Mrs. John R. Lawson
Mr. and Mrs. Frank Layton
The Learning Tree Preschool
Mr. and Mrs. Christopher A. Lee
Mr. and Mrs. Michael G. Leonard
Ms. Michelle L. LeRoy
Mr. and Mrs. Joseph A. Leto
Ms. Karin L. Levesque
Ms. Jennifer Lovell
Mr. and Mrs. Gary W. Lewis
Mr. and Mrs. George W. Little
Mr. and Mrs. William H. Litton
Mr. and Mrs. William S. Livolsi
Ms. Tiffany Locklear
Ms. Terry L. Long
Longleaf Leasing Partners
Ms. Janet G. Lopuz
Mr. and Mrs. Harold C. Luppens
Ms. Susan M. Lynch
Lynch Law Firm
Dr. and Mrs. Nicholas J. Lynn
Mr. and Mrs. Peter C. Mace
Mr. and Mrs. Raymond G. MacKay, Jr.
Mr. and Mrs. Henry F. Magnuson
Mr. Alan G. Majka
Ms. Kristen R. Malouf
Ms. Sherril L. Mangum
Mr. and Mrs. Paul Manley
Mr. and Mrs. E. L. Manning
Mr. and Mrs. John E. Manoney
Mr. Tyler Marriott
Mr. and Mrs. Daniel Martin
Mr. and Mrs. Michael G. Martin
Ms. Sarah G. Martin
Ms. Kim Mason
Mr. and Mrs. C. Bruce Matthews
Ms. Diana B. Matthews
Mr. and Mrs. Kevin P. Matthews
Ms. Pat Mayhew
Dr. and Mrs. Brooks B. Mays
Mrs. Barbara McAllister
Mr. and Mrs. John J. McCarthy
Dr. Fred B. McCashin
Mr. and Mrs. Mitchell W. McCaskill
Mr. and Mrs. B. R. McConnell, Jr.
Mr. Thomas C. McCormick
Colonel and Mrs. Richard F. McCrory
Dr. and Mrs. William D. McDearmon
Mr. and Mrs. Joseph A. McDonald
Mr. and Mrs. John M. McDougall
Ms. Kelly McElroy
Mr. and Mrs. Gary R. McGeary
Mr. and Mrs. James J. McGillan
Mr. Richard A. McGowan
Colonel (Ret.) Charlie T. McGhug
Dr. and Mrs. Wyman T. McGurk
Mr. Thomas McHale
Mr. and Mrs. Roderick W. McVier, Jr.
Mr. and Mrs. B. Donald McKenzie
McKenzie Photography, LLC
Mr. Frederick A. McKenzie
Mr. and Mrs. Ralph C. McKenzie
Mr. and Mrs. Randy Mehan
Colonel (Ret.) and Mrs. Marvern M. Mercer
Menendez & Ritter Retirement
Group of Wells Fargo Advisors
Meridian Zero Degrees
Ms. Carol A. Meningolo
Mr. and Mrs. Robert T. Merrell
Ms. Julia Merritt
Mrs. June A. Metro
Mr. and Mrs. Anthony R. Metzger
Ms. Susanne T. Meyer
Ms. Joanne E. Milatke
Ms. Mandy Midgrett
Mr. and Mrs. Michael G. Mikurak
Mr. Brandon W. Miller
Mr. and Mrs. Clifton W. Miller
Mr. and Mrs. Norman T. Minery
Ms. Britany F. Minoque
Dr. and Mrs. C. Kenneth Mitchell, Jr.
Mr. Roy Mitchell
Ms. Maria P. Mitchum
Mrs. Georgia C. Moffitt
Mr. and Mrs. Jeff F. Mohn
Ms. Sharon A. Molis
Mr. and Mrs. David A. Mongillo
Mr. Christopher D. Monroe
Mr. and Mrs. G. Bruce Monteith
Monteith Construction
Mr. Seth Moria and Mrs. Christine Vandeveer
Mr. and Mrs. C. S. Morris
Mr. and Mrs. Colen L. Morrison
Mr. and Mrs. Bill M. Moses
Mrs. Carolyn C. Mosseller
Mr. and Mrs. Craig Moulton
Mr. and Mrs. Tom Moyhain
Ms. Donna C. Munigua
Mr. Joseph M. Munn
Colonel (Ret.) and Mrs. Richard M. Murphy
Mr. and Mrs. Thomas L. Murphy
Mr. and Mrs. David C. Myers, Jr.
Mrs. Marion M. Myers
Mr. and Mrs. Jack Nance
Mr. Corey Nash
Mr. Jared Nelson
Ms. Jamie J. Newell
Mr. and Mrs. Ron Newland
Mr. and Mrs. Ralph S. Newman, Jr.
Mr. and Mrs. Sidney Newman
Mr. and Mrs. James R. Nichols
Ms. Dorothy L. Nicholson
Mr. and Mrs. Rodney B. Nordman
Ms. Jen Norris
Mr. and Mrs. Fred G. Nuinighoff
Mr. and Mrs. Patrick Nugent
O’Callahan Society
Mr. and Mrs. Bernard F. O’Connell
Ms. Melissa O’Connor
Mr. and Mrs. Donald Oldham
Mr. and Mrs. Richard J. Oldham
Mrs. Pete Olson
Mr. and Mrs. John M. Oliver, Jr.
Mr. Tyler O’Neill
Mr. Nick Onyango
Mr. and Mrs. Louis Orefice
Ms. Rudee Orians
Mr. Santiago W. Ortega
Ms. Beth Osborn
Mr. and Mrs. Colin Oswald
Mr. and Mrs. Ulysses Otero
Mrs. Anne Overstreet
Mr. and Mrs. John Owen
Mr. and Mrs. John C. Owen
Mr. and Mrs. William E. Owen
Mr. and Mrs. John C. Owen
Ms. Robert W. Owen
Ms. Christine Owen
Mr. and Mrs. Stem Owen
Mr. and Mrs. Walter Owen
Mr. and Mrs. William E. Owen
Ms.ቲa Owen
Mr. and Mrs. Caleb Owen
Ms. Tracie S. Patterson
Ms. Molly Patterson
Mr. and Mrs. William R. Parke
Mrs. Angel F. Palumbo
Harwell Palmer, DDS, PA
Mr. and Mrs. Robert W. Parke
Mr. and Mrs. William R. Parke
Ms. Isabelle Parker
Ms. Angela T. Parks
Mr. and Mrs. Colin Oswald
Mr. and Mrs. Ulysses Otero
Mrs. Anne Overstreet
Mr. and Mrs. John Owen
Mr. and Mrs. John C. Owen
Mr. and Mrs. William E. Owen
Mr. Ethan Owens
Mr. Scot Padgett
Harwell Palmer, DDS, PA
Ms. Angela T. Parks
Mr. and Mrs. Colin Oswald
Mr. and Mrs. Ulysses Otero
Mrs. Anne Overstreet
Mr. and Mrs. John Owen
Mr. and Mrs. John C. Owen
Mr. and Mrs. William E. Owen
Mr. Ethan Owens
Mr. Scot Padgett
Harwell Palmer, DDS, PA
Ms. Angela T. Parks
Mr. and Mrs. Colin Oswald
Mr. and Mrs. Ulysses Otero
Mrs. Anne Overstreet
Mr. and Mrs. John Owen
Mr. and Mrs. John C. Owen
Mr. and Mrs. William E. Owen
Mr. Ethan Owens
Mr. Scot Padgett
Moore Regional Hospital Foundation – Cancer CARE Fund Benefactors (continued)

Mr. Andrew J. Pennick
Mr. and Mrs. Orlando Perez
Ms. Jackie Perkins
Reverend Grady J. Perryman
Ms. Ann M. Peters
Ms. Jean Lawson Peters
Ms. Carrie Peterson
Mr. and Mrs. William Peterson
Dr. and Mrs. DeWitt R. Petterson
Mr. Christopher Pevia
Ms. Monica Pevia
Mr. and Mrs. Robert T. Pfrunder
Mr. and Mrs. Landis J. Phillips
Piedmont Natural Gas
Ms. Tara J. Pike
Ms. Avis C. Pilewski
Ms. Tara J. Pike
Pinehurst Resort and Country Club
Dr. and Mrs. Lawrence B. Place
Mr. and Mrs. Christopher B. Plonsky
Mr. Marijn Pols
Dr. Michael C. Pooch
Mr. and Mrs. Joseph C. Poole
Mr. and Mrs. David Pope
Ms. Tenissa A. Pope
Mr. and Mrs. John L. Powell
Ms. Susan J. Pressley
Mrs. Carol F. Prevatte
Mr. and Mrs. Joseph P. Ptaszek
Mr. and Mrs. George E. Puckett
Mr. and Mrs. Phil M. Pugh
Dr. and Mrs. Vincent T. Pullo
Mr. Geoffrey C. Purser and
Dr. Susan R. Purser
Mr. Jesse Putney
Mr. David Quintan
Mr. and Mrs. William L. Ramme
Mr. Mark A. Rassald
Mr. and Mrs. Joseph J. Rasmus
Mr. and Mrs. Mark Rea
Ms. Maria J. Rebellot
Mr. and Mrs. Todd R. Redenbaugh
Mr. and Mrs. W. Thomas Reedy
Mr. and Mrs. James G. Reid, Jr.
Dr. Matthew F. Reinhardt and
Dr. Claire E. Reinhardt
Mr. Gricastro Reyes
Mr. Jose Reyne
Ms. Crystal L. Richardson
Mr. and Mrs. Charles W. Ridenhour
Ms. Carrie L. Riggle
Mr. Kevin Riley
Mr. and Mrs. Roger S. Rinehart
Ms. Lemone Rittenhouse
Mr. and Mrs. William A. Roberts
Mr. and Mrs. Tait A. Robinson
Mr. Craig A. Rodland
Ms. Athena Rogers
Mr. and Mrs. P. Fred Rose
Ms. Angelica Ross
Ms. Sylvia M. Rowland
Ms. Emily V. Rubino
Mr. and Mrs. Paul Rudovsky
Ms. Charissa D. Russ
Mr. and Mrs. Michael B. Russell
Ms. Julia Russell
Mr. and Mrs. Timothy M. Ryan
Mr. and Mrs. Brandon M. Sampson
Sandhills Classic Street Rod
Association
Sandhills Emergency Physicians
Sandhills Pediatrics
Mr. and Mrs. William K. Sauder
Mr. and Mrs. James W. Saunders
Ms. Deborah Sawyer
Ms. Erin Shabill
Ms. Brianna C. Schantz
Dr. and Mrs. Charles C. Schirmer
Mr. and Mrs. Robert A. Schlicht
Mr. Walter Schmiedeskamp
Mr. and Mrs. Larry J. Schramm
Mr. and Mrs. Ronald H. Schuch
Ms. Sue A. Schwartz
Mr. and Mrs. Ian Scott
Mr. and Mrs. Mark A. Scott
Mr. and Mrs. Mark S. Scott
Mr. and Mrs. Erick N. Scroggins
Mr. and Mrs. Brandon Seabolt
Ms. Sandra Seay
Mr. and Mrs. John Secrist
Mr. and Mrs. David E. Seifried
Mrs. Donna H. Sennett
Mr. and Mrs. Franklin T. Sessions
Seven Lakes Prescription Shoppe
Ms. Birtha Shaw
Mr. and Mrs. Christopher R. Shaw
Colonel and Mrs. Thomas C. Shaylor
Mrs. Beverly J. Shebs
Ms. Ella C. Sheen
Mr. Blake M. Shelton
Mr. and Mrs. Michael P. Shepard
Dr. John D. Shepherd and
Dr. Jenifer J. Bruno
Ms. Rebecca L. Sherman
Ms. Nova Sherry
Mr. and Mrs. William F. Shikhitus
Mr. Nicholas J. Lockie and Mrs.
Jessica L. Shoecraft-Locke
Ms. Renee D. Siemiet
Mr. and Mrs. Henrique A. Silva
Mrs. Mary Silverman-Ormond
Ms. Kishon Simon
Dr. and Mrs. Darrell G. Simpkins
Mr. Steve Sims
Ms. Kathleen Sippy
Ms. Phyllis M. Sixmore
Ms. Patricia A. Skinner
Ms. Jean Skora
Small Animal Emergency Services
Mrs. Beverly Collins Smith
Mr. and Mrs. Charles K. Smith
Mr. Jamie P. Smith
Mr. and Mrs. Jeffrey S. Smith
Ms. Lea Smith
Mrs. Melinda H. Smith
Ms. Susan L. Smith
Mr. and Mrs. Tanya R. Smith and
Mr. Tom Loy
Mr. Thomas P. Smith
Mr. and Mrs. Jason P. Snyder
Mr. and Mrs. William S. Sobot
Ms. Judith Soto
Mr. Jean Souweine and
Mrs. Joel C. Rich
Southern Pines Physical Therapy
Southmore Heating & Cooling, Inc.
Mr. and Mrs. Herchel G. Spears
Ms. Kim C. Spears
Mr. Aaron Spera
Mr. Bernard C. Spielhagen
Mr. Ken Squires
Mr. and Mrs. Ian C. Stack
Ms. Julia Stallings
Mr. John Stankowski
Ms. April Stanley
Mr. and Mrs. Stephen Stanley
Mr. and Mrs. James R. Stapleton
Mrs. Frances V. Stark
Dr. and Mrs. E. Wilson Staub
Mr. and Mrs. Andrew Steiding
Mr. Murray Stein
Ms. Linda C. Stevens
Ms. Janice P. Stewart
Mr. Nicholas S. Stewart
Mr. and Mrs. Rodney Stewart
Dr. and Mrs. William L. Stewart
Mr. Erik Stillinger
Mr. and Mrs. Forrest D. Stine
Colonel and Mrs. Charles E. Stockham
Mr. and Mrs. John C. Stockwell
Mr. and Mrs. Edwin N. Storms
Mr. Robert C. Stout
Ms. Katie Strange
Ms. Lorin Strange
Mrs. Jeanne H. Street
Mr. and Mrs. Erik Stromberg
Mrs. Cynthia D. Strother
Mr. John C. Stroud, III
Mr. Timothy R. Sullivan
Mr. and Mrs. Lynn C. Summers
Mr. and Mrs. Walter E. Sutter
Mr. and Mrs. Edward R. Swan
Mr. and Mrs. Marshall R. Sweatt
Mr. and Mrs. James A. Tanski
Mr. and Mrs. Edward T. Tawes, Jr.
Mr. Bob L. Taylor
Mr. and Mrs. David R. Taylor
Mr. and Mrs. Gilbert L. Taylor
Mr. James Taylor
Mr. and Mrs. Roger N. Taylor, Jr.
Major and Mrs. Brett A. Tecklenburg
Dr. and Mrs. William V. Terry
Mr. and Mrs. Benjamin Tewelliger
Mr. and Mrs. Harold A. Theiste
Ms. Judy L. Theriot
Ms. Alice S. Thomas
Mr. and Mrs. Donald G. Thomas
Mrs. Jean C. Thomas
Mr. and Mrs. J. Keith Thomasson
Ms. Jennifer B. Thompson
Mr. Brian L. Thomsen and
Ms. Eunice V. Johnson
Mr. and Mrs. Chuck Tinker
Ms. Kelly Tontolent
Mr. and Mrs. Heath Trust
Mr. and Mrs. John W. Tucker, Jr.
Mr. and Mrs. Richard W. Tufts
Mr. and Mrs. J. T. Tufts
Mr. and Mrs. David J. Turk
Mr. and Mrs. Billy Turner
Dr. and Mrs. John T. Turner
Mr. and Mrs. Robert E. Tweed
Mr. and Mrs. David T. Uphurgh
Ms. Kelly Valdes
Ms. Judith P. Valvo
Ms. Dianne Van Winkle
Mrs. Anne S. VanderWolk
Mr. Richard Varquez
Mr. Jose Vasquez
Vass Women's Club
Mr. David Verchick and
Dr. Julie G. Verchick
Mr. and Mrs. David W. Venneflihn
Mr. and Mrs. Dominic Vitalo
Mr. and Mrs. Harry Vogt
Mr. Bryan Waldo and
Dr. Aikya Waldo
Mr. and Mrs. Derek Walker
Mr. and Mrs. Glen Wallace
Mr. and Mrs. Henry E. Wallace
Mr. and Mrs. Charles V. Walters
Mr. and Mrs. Ronald V. Ward
Ms. Tonia Warner
Mr. and Mrs. Howard J. Warren
Mr. Michael Wachschen
Dr. Raymond G. Washington and
Dr. Tori A. Washington
Mr. and Mrs. Paul Wasta
Mr. and Mrs. Michael F. Watson
Ms. Linda W. Webb
Mr. and Mrs. Charles B. Webster
Ms. Dolores Weber
Ms. Heather A. Weeks
Mr. and Mrs. Randolph E. Weibl
Mr. and Mrs. Blaine Weiers
Mr. Eric Welden
Mr. and Mrs. Joseph T. Welsh
Mr. and Mrs. Scott Wesner
Ms. Mary Lynn H. West
Mr. and Mrs. Thomas L. West
Mr. and Mrs. Robert F. Wetherbee
Mr. and Mrs. Joseph D. Wheliss
Ms. Diana White
Mr. Jason B. White
Mr. June C. White
Mr. and Mrs. Ricky L. Wicker
Mr. Steven Wilkes
Mr. and Mrs. Chan Williams
Mrs. Connie L. Williams
Sergeant Major (Ret) and
Ms. David Williams
Mr. and Mrs. Densel Williams
Mr. and Mrs. Paul M. Williams
Ms. Rae R. Williams
Mr. Rex K. Williams
Mr. and Mrs. Murray Williamson
Mr. and Mrs. Daniel D. Willett
Mr. and Mrs. Robert D. Wilson
Mr. Sherry M. Wilson
Ms. Judy R. Wimmer
Mr. and Mrs. Bruce K. Winn
Ms. Christina J. Winn
Mr. and Mrs. Charles Wolf
Ms. Sherry Wolfgang
Women of the Pines
Mr. and Mrs. Donald A. Wood
Mr. and Mrs. Jack B. Wood
Mrs. Clara Woodcock
Mr. and Mrs. F. David Woodruff
Mr. and Mrs. Brad Woodward
Ms. Rhonda Woodward
Mr. and Mrs. Dennis N. Wooten
Mr. and Mrs. Malcolm Wright
Mrs. Carole A. Wunderlin
Mr. and Mrs. Charles S. Wunsch
Wyoming High School Math
Department
Mrs. Mary Ann Yakel
Mr. and Mrs. Robert E. Yates
Mr. and Mrs. Jeffrey M. Zampa
Mr. and Mrs. Frank J. Zehnder
Mr. and Mrs. Charles J. Zuhone